Genentech and Biogen roll the dice on an upstart biotech with a new siRNA approach — going deep into the brain for targets in neurodegeneration
Atalanta isn’t your average stealth biotech making a debut. They have some history and deals to sketch out in rough outlines.
The founding execs date the silent launch all the way back to mid-2019, with the publication of a seminal study looking at a new siRNA strategy for neurodegeneration. And instead of scouting for their first partners, the fledgling biotech can already count 2 prominent players as allies in the extensive preclinical work that’s been done to establish the platform.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 158,500+ biopharma pros reading Endpoints daily — and it's free.